IMRX vs. INBX, PRQR, HURA, DMAC, ACIU, IKT, ESPR, DERM, NBTX, and FDMT
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Inhibrx (INBX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), DiaMedica Therapeutics (DMAC), AC Immune (ACIU), Inhibikase Therapeutics (IKT), Esperion Therapeutics (ESPR), Journey Medical (DERM), Nanobiotix (NBTX), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry.
Immuneering vs.
Inhibrx (NASDAQ:INBX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.
82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 17.1% of Inhibrx shares are owned by company insiders. Comparatively, 25.0% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Immuneering has a consensus target price of $15.33, indicating a potential upside of 895.67%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than Inhibrx.
Immuneering received 7 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 70.37% of users gave Immuneering an outperform vote while only 57.41% of users gave Inhibrx an outperform vote.
Immuneering has higher revenue and earnings than Inhibrx. Immuneering is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
Immuneering's return on equity of -79.19% beat Inhibrx's return on equity.
In the previous week, Inhibrx had 5 more articles in the media than Immuneering. MarketBeat recorded 5 mentions for Inhibrx and 0 mentions for Immuneering. Inhibrx's average media sentiment score of 1.22 beat Immuneering's score of 0.00 indicating that Inhibrx is being referred to more favorably in the media.
Summary
Immuneering beats Inhibrx on 10 of the 16 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
This page (NASDAQ:IMRX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy IMRX Stock Free IMRX Stock Alerts